FREMONT, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced a strategic
MORRISTOWN, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Alfasigma, a global pharmaceutical company, today announced that five presentations on linerixibat in primary biliary cholangitis (PBC), including one oral
Approval based on phase III data showing unprecedented functional cure rates compared to standard of care
Six-month treatment with option of self-administration after first dose
CHB affects approximately 1.7
Approval based on AZUR-1 data showing clinically significant proportion of participants with no detectable signs of cancer one year or more after treatment
No disease recurrences reported among responders after
For the first time, Viola Davis shares her experience with shinglesViola encourages adults 50 years and older to prioritize their health and have candid conversations about increased risks that come with agingThe
All dollar ($) figures in Canadian dollars unless otherwise noted.TORONTO, Aug. 24, 2026 /CNW/ -- Canadian venture capital (VC) investment totalled $2.481 billion across 248 financings in the first half of 2026,
Nearly 9 in 10 Canadians have little to no awareness of chronic hepatitis B (CHB)Only 31% rank CHB as a high cancer risk, revealing a significant gap between perception and realityJust 14% report to have been tested for
Approval based on ARROS-1 phase I/II trial demonstrating meaningful and durable responses in patients with locally advanced or metastatic disease1Next-generation design aims to address key efficacy and tolerability
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Nuvalent, Inc. (NASDAQ:NUVL) to GSK plc (NYSE:GSK).
AUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Oncology research is moving through one of its most active stretches in years. DNA Damage Response ("DDR") inhibitors, a category
First and only oral carbapenem antibiotic approved in the US
Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1
More than 3 million cases of cUTIs are treated
First and only oral carbapenem antibiotic approved in the USApproval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatmentiMore than 3 million cases of cUTIs are treated annually in the
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Nuvalent, Inc. (NASDAQ:NUVL) to GSK plc (NYSE:GSK). Under the
DENVER, June 09, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Artificial intelligence continues to dominate healthcare headlines, but another transformative story is quietly unfolding across biotechnology: the
Issued on behalf of GT Biopharma, Inc. SAN FRANCISCO, May 18, 2026 /CNW/ -- USA News Group News Commentary — For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody
